ELIXIRGEN
Live / Registered — Registered — Section 8 accepted (as of 27 Sept 2023)
What this means for you
Registered since 31 Oct 2017. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87190457
- Registration number
- 5320821
- Mark type
- Design + words
- Filed
- 01 Oct 2016
- Published for opposition
- 15 Aug 2017
- Registered
- 31 Oct 2017
- Attorney of record
- Leonard D. Bowersox
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations and substances for the treatment of telomere-shortening diseases (e.g., dyskeratosis congenita, Fanconi anemia, idiopathic and pulmonary fibrosis), karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, cancer; chemicals and chemical preparations for medical and pharmaceutical purposes for telomere-shortening diseases (e.g., dyskeratosis congenita, and Fanconi anemia), idiopathic pulmonary fibrosis, karyotype abnormalities (e.g., Down syndrome, and Edwards Syndrome), motor neuron diseases (e.g., Amyotrophic lateral sclerosis, multifocal neuropathy, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and pseudobulbar palsy), muscular diseases (e.g., Muscular atrophies, muscular growth, myopathy diseases, muscular disorders, muscular dystrophy, myositis, neuromuscular diseases, and sarcopenia), diseases related to the brain, diseases related to the spine, and cancers
- Class 042 — Scientific and technological services: Development of pharmaceutical products for others; product quality testing and evaluation for others; research and development of pharmaceutical products for others; research and development of medical products for others
Owner
- Elixirgen, LLC, Baltimore, MD, US
- Elixirgen, LLC, Baltimore, MD, US
- Elixirgen, LLC, Baltimore, MD, US
Prosecution history
- 30 Jan 2026 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 27 Sept 2023 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 27 Sept 2023 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 26 Sept 2023 — TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
- 23 Aug 2023 — POST REGISTRATION ACTION MAILED - SEC. 8
- 22 Aug 2023 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 21 Mar 2023 — TEAS SECTION 8 RECEIVED
- 17 Mar 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 17 Mar 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 Mar 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 17 Mar 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Mar 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 31 Oct 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 31 Oct 2017 — REGISTERED-PRINCIPAL REGISTER
- 15 Aug 2017 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED